Loading
Millions of people have had weight-loss surgery or now take weight-loss drugs. Linking those records to cancer registries would show, cancer by cancer, how much reversing obesity prevents, for almost no cost.
Nordic registries and the Cleveland Clinic SPLENDID cohort show about a third fewer obesity-related cancers after bariatric surgery, but individual sites (oesophageal adenocarcinoma, colorectal, pancreatic) are underpowered, and the emerging GLP-1 receptor agonist data are from insurance claims with short follow-up. Most high-income countries have national bariatric surgery registries, complete cancer registries and prescription databases; a federated linkage with a common protocol would produce site-specific, sex-specific estimates, detect any unexpected harm (post-bariatric colorectal cancer, thyroid), and provide the counterfactual against which GLP-1 drugs can be judged.
Shares Bariatric surgery and cancer incidence, GLP-1 receptor agonists and obesity-related cancer risk, Obesity-related cancers (IARC list of 13), Endometrial cancer.
Shares A trial of GLP-1 weight-loss drugs with cancer as the primary outcome, Prevention we already have is not deployed, Endometrial cancer, Renal cell carcinoma.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Karolinska University Hospital, Real-world evidence, Weak real-world evidence and registries.
Shares Obesity-related cancers (IARC list of 13), Endometrial cancer, Renal cell carcinoma, Hepatocellular carcinoma.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries, Data silos.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.
Shares Assessment of the Clinical Benefit of Cancer Drugs Receiving Accelerated Approval, Real-world evidence, Weak real-world evidence and registries.